The presence of aggregates of abnormally expanded polyglutamine (polyQ)-containing proteins are a pathological hallmark of a number of neurodegenerative diseases including Huntington's disease (HD) and spinocerebellar ataxia-3 (SCA3). Previous studies in cellular, Drosophila, and mouse models of HD and SCA have shown that neurodegeneration can be prevented by manipulations that inhibit polyQ aggregation. We have shown that the UL97 kinase of the human cytomegalovirus (HCMV) prevents aggregation of the pp71 and pp65 viral tegument proteins. To explore whether UL97 may act as a general antiaggregation factor, we examined whether UL97 prevents aggregation of cellular non-polyQ and polyQ proteins. We report that UL97 prevents the deposition of aggregates of two non-polyQ proteins: a protein chimera (GFP170*) composed of the green fluorescent protein and a fragment of the Golgi Complex protein (GCP-170) and a chimera composed of the red fluorescent protein (RFP) fused to the Werner syndrome protein (WRN), a RecQ helicase and exonuclease involved in DNA repair. Furthermore, we show that UL97 inhibits aggregate deposition in cellular models of HD and SCA3. UL97 prevents the deposition of aggregates of the mutant huntingtin exon 1 containing 82 glutamine repeats (HttExon1-Q82) or full length ataxin-3 containing a 72 polyQ track (AT3-72Q). The kinase activity of UL97 appears critical, as the kinase-dead UL97 mutant (K335M) fails to prevent aggregate formation. We further show that UL97 disrupts nuclear PML bodies and decreases p53-mediated transcription. The universality of the antiaggregation effect of UL97 suggests that UL97 targets a key cellular factor that regulates cellular aggregation mechanisms. Our results identify UL97 as a novel means to modulate polyQ aggregation and suggest that UL97 can serve as a novel tool to probe the cellular mechanisms that contribute to the formation of aggregates in polyglutamine disorders.
Introduction
The expansion of trinucleotide CAG repeats encoding glutamines within specific cellular proteins is the cause of inherited neurodegenerative diseases termed polyglutamine disorders. Huntington's disease, spinobulbar muscular atrophy (SBMA), dentatorubral-pallidoluysian atrophy (DRPLA), and spinocerebellar ataxias (SCA) 1, 2, 3, 6, 7, and 17 are all caused by an abnormally expanded polyQ domain (reviewed in Cummings and Zoghbi, 2000; McCampbell et al., 2001; Orr and Zoghbi, 2007) . A striking neuropathological hallmark of these polyQ diseases is the presence of neuronal insoluble cytoplasmic aggregates and nuclear insoluble inclusions (NIIs) formed by mutant polyQ proteins (reviewed in Ross, 2002) . The role NIIs and cytoplasmic aggregates in the pathological processes of polyQ diseases remains contentious. While some consider the NIIs/cytoplasmic aggregates as direct toxic intermediates, some have proposed that NIIs/cytoplasmic aggregates are a point of sequestration of a toxic product and thereby beneficial to a neuron (Arrasate et al., 2004; Ross et al., 1999) .
Multiple lines of evidence support the view that protein aggregation is a complex process that is initiated by the accumulation of misfolded polyQ-containing proteins into a variety of higher-order intermediate conformational assemblies that ultimately form insoluble inclusion bodies. Conformational rearrangements of these mutated proteins likely change their biological activities and contribute to their toxicities. Importantly, recent reports suggest that the toxicity of mutant polyQcontaining proteins might be not related to the insoluble inclusion bodies but rather to soluble oligomeric or other intermediate conformations (Kayed et al., 2003 (Kayed et al., , 2004 . In support of this idea, polyQinduced neurodegeneration can be prevented by pharmacological and molecular manipulations that target processes leading to oligomerization and aggregation. For instance, inhibition of polyglutamine oligomerization in a transgenic mouse model of HD has a marked protective effect on survival, weight loss, and motor function (Sanchez et al., 2003) , supporting the idea that oligomerization of expanded Neurobiology of Disease 41 (2011) 11-22 
